4 Healthcare Stock Stories for Tuesday Wellness
January 29, 2013
Oncolytics Biotech (NASDAQ:ONCY): Closing price $3.55
On Monday, the company announced a poster presentation that covers positive preliminary results from a Phase I evaluation examining the intravenous administration of Reolysin in combination with Folfiri in patients suffering from metastatic colorectal cancer (REO 022). The results were presented at the ASCO Gastrointestinal Cancers Symposium in San Francisco, which took place from January 24th through the 26th.
Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!
Premium Newsletters
Gold & Silver
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More
Commodities Premium
There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more
ETF Investing
At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more
Wall St. Cheat Sheet has been featured in these fine media outlets:
